Baker M A, Taub R N, Carter W H, Davidson M, Sutton D M, Kutas G, Berger S, Watt H J
Cancer Res. 1984 Jan;44(1):383-5.
Thirty-one consecutive patients with chronic myelogenous leukemia were treated in the chronic phase with immunotherapy in addition to chemotherapy. Immunotherapy consisted of Bacillus Calmette-Guérin and allogeneic myeloblasts given by vaccination, and chemotherapy comprised busulfan p.o. in most patients. No randomly allocated control group was designated, but patient characteristics appear to be typical of those of other published groups. Twenty-eight of 31 patients were followed from diagnosis to death, and the three remaining patients were followed for over 5 years. The median survival of the patients in our group was 37 months. There was a constant rate of decline in survival with time, with a mean annual death rate of 30% per year. Twenty-five of the 31 patients terminated in blast crisis. One of 21 patients achieved complete remission in blast crisis of myeloid or indeterminate type, and three of four patients achieved complete remission for blast crisis of lymphoid type. The median survival, the rate of decline in survival, and the remission rate in blast crisis do not appear to differ from those of comparable groups of patients treated with chemotherapy alone.
31例慢性粒细胞白血病患者在慢性期除接受化疗外还接受了免疫治疗。免疫治疗包括通过接种卡介苗和同种异基因成髓细胞进行，化疗在大多数患者中采用口服白消安。未设立随机分配的对照组，但患者特征似乎与其他已发表组的患者典型特征相符。31例患者中有28例从诊断到死亡均接受随访，其余3例患者随访超过5年。我们组患者的中位生存期为37个月。生存率随时间持续下降，平均年死亡率为每年30%。31例患者中有25例最终发生急变期。21例髓系或未定型急变期患者中有1例实现完全缓解，4例淋巴系急变期患者中有3例实现完全缓解。中位生存期、生存率下降率以及急变期缓解率似乎与仅接受化疗的类似患者组没有差异。
